anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method and system for doing patient de-identification provides that various DICOM tags that need to be masked or encrypted can be easily configured in the system parameters of a healthcare provider's CAS. Whenever the user selects to export any image outside PACS, the CAS is looked for to check if the system forces de-identification or gives the user the choice for de-identification. If the de-identification needs to be done forcefully, then all the configured DICOM tags are extracted from the CAS and stored in the application for performance enhancement. The application then applies the extracted logic while exporting all the selected images and masks all DICOM tags listed in the CAS to be masked. If the system does not enforce de-identification, then the CAS returns only the list of the DICOM tags to be exported, which are then cached in the application for performance purposes. The user is then prompted to do patient de-identification manually and is also prompted for the choice of the masking for the selected DICOM tags. The images are then exported by masking the listed DICOM tags and keeping the rest of the DICOM tags as if they are on the exported image, in any format.
Small molecule agonists, partial agonists, and antagonists for the TrkA receptor are described. The compounds are gambogic amines, where the carboxylic acid group of gambogic acid (CO 2 H) has been replaced by an amine group (CH 2 NR 1 R 2 ). In some embodiments, the compounds selectively bind to TrkA but not TrkB or C, robustly induce its tyrosine phosphorylation and downstream signaling activation including Akt and MAP kinases. Further, they can strongly prevent glutamate-induced neuronal cell death and provoke prominent neurite outgrowth in PC12 cells. Gambogic amines specifically interact with the cytoplasmic juxtamembrane domain of TrkA receptor and trigger its dimerization. Administration of these compounds in can substantially diminishes Kainic acid-triggered neuronal cell death and decrease infarct volume in transient middle cerebral artery occlusion (MCAO) model of stroke. Thus, these compounds can provide effective treatments for debilitating neurodegenerative diseases and provide neuroprotection from patients suffering from stroke or other ischemic events.
BACKGROUND: As a result of the world population and climate change impact increases (especially in arid environments), there is a critical need for high-yield, drought-tolerant wheat. Synthetic hexaploid wheat derived lines (SHW-DL), were created artificially by crossing different durum wheat cultivars (AABB) with accessions of Aegilops tauschii (DD), a beneficial source of new genes for common bread wheat (Triticum aestivum L). Here, we studied the response of a panel of 91 SHW-DL for drought tolerance based on physiological, antioxidant enzyme activities, and drought tolerance indices.
RESULTS: A wide range of variation and high values of heritability observed for grain yield, physiological and antioxidant traits indicating that the SHW-DL panel constitutes a valuable gene source for drought tolerance improvement of wheat. Despite decreases in grain yield (YLD), leaf area index (LAI), and relative water content (RWC) an increase in the content of malondialdehyde (MDA) was observed. Moreover, drought streass increased the antioxidant enzyme activities of ascorbate peroxidase (APX), catalase (CAT) and peroxidase (POD), and also photosynthetic pigments, proline (Pro), and MDA content. With higher values of grain yield, physiological and biochemical traits such as photosynthetic pigments, and RWC, and lower content of MDA, and peroxidase (H2O2) activity, SHW-DL performed better compared to common wheat lines under water stress conditions.
CONCLUSIONS: Different responses to water stress within the germplasm and between synthetic and common wheat suggest that selection for adaptive and suitable genotypes is possible for drought tolerance in synthetic wheat germplasm. Genotypes 54, 98, 102, 105, 122, 124, 143, 159, 196, and 198 were identified to be directly used in breeding programs or indirectly by crossing them with other wheat germplasm collections.
The present invention discloses a preparing technology of target ribonuclease for treating the infection of hepatitis B virus. The technology uses a molecular biology method to construct fusion protein of neurotoxin hEDN and HBV polymerase terminal protein structural domain DNAPTP or core protein which are the sources of human eosinophilic granulocyte. The fusion protein is constructed target ribonuclease. The fusion protein can adopt a gene treatment or protein medicine mode to treat the infection of the hepatitis B virus of a person. An experiment indicates that the target ribonuclease constructed by the present invention can cause hepatitis B virus surface antigens (HBSAg) to be reduced by 46% to 59% in vitro, and the replication of the hepatitis B virus can be suppressed obviously. The concrete medicine supplying route and the medicine supplying mode can refer the existing gene treatment or protein medicine scheme.
For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and will contain space to write a specific physical activity goal and to track physical activity (e.g., through step counter data) over the subsequent week. At the in-person visit #2, interventionists will explain PP exercise 1 and MI session 1 to the participants. Calls will last \~30 minutes. Participants will then independently complete PP exercises and MI-based goals and review them at phone sessions over 12 weeks. PP and MI components will be delivered stepwise within sessions (rather than intertwined) based on our experience, participant feedback, and pilot work.
Background: Naldemedine, a peripherally acting opioid μ receptor antagonist, is effective for prevention of opioid-induced constipation (OIC); however, evidence on its use in children is limited. Objective: To evaluate the efficacy and safety of naldemedine in pediatric patients with OIC. Design, Setting/Subjects: Retrospective analysis of 32 pediatric patients with OIC treated with naldemedine in a single institution in Japan from June 2017 to March 2021. Measurements: Efficacy was evaluated in 13 evaluable patients with bowel movement (BM) response, defined as those with at least three BMs in the first 7 days after naldemedine initiation and an increase of at least one BM from baseline. Safety was evaluated by examining adverse events (AEs) based on the Common Terminology Criteria for AEs (v5.0). Results: BM response was recorded in 11 of the 13 patients (85%), and the number BMs per day significantly increased from 0.43 before naldemedine to 1.00 after naldemedine (p = 0.025). The most common AE was diarrhea, observed in 16 of the 32 patients (50%), and all instances were grade 1 or 2. In three of the 16 patients, naldemedine was discontinued owing to worsening diarrhea. Conclusions: In pediatric patients, naldemedine resulted in a high rate of BM response and increased the BM frequency, indicating its efficacy. In some patients, grade 2 diarrhea required naldemedine discontinuation, suggesting that it should be used with caution in pediatric patients. Further studies are warranted to determine the optimal naldemedine dose in pediatric patients.
Untreated participants who served as controls in the antecedent study 273CH301 (NCT03496012), investigating treatment with BIIB111, will be enrolled. This is a follow-up study, participants will not be administered study medication nor receive a sham surgery.
The androgens are steroids that develop and maintain primary and secondary male sex characteristics.

Androgens are derivatives of cyclopentanoper-hydrophenanthrene. Endogenous androgens are C-19 steroids with a side chain at C-17, and with two angular methyl groups. Testosterone is the primary endogenous androgen. In their active form, all drugs in the class have a 17-beta hydroxy group. 17-alpha alkylation (methyltestosterone) increases the pharmacologic activity per unit weight compared to testosterone when given orally.

Methyltestosterone, a synthetic derivative of testosterone, is an androgenic preparation given by the oral route in a capsule form. It has the following structural formula:

C20H30O2 M.W. 302.46

17-β-hydroxy-17-methylandrost-4-en-3-one

Methyltestosterone, USP occurs as white or creamy white crystals or powder, which is soluble in various organic solvents but is practically insoluble in water.

Each capsule, for oral administration, contains 10 mg of methyltestosterone, USP. In addition, each capsule contains the following inactive ingredients: corn starch, D&C Yellow #10, gelatin, FD&C Blue #1, FD&C Red #40, and magnesium stearate. Additionally, the capsule printing inks contain D&C Yellow #10, FD&C Blue #1, FD&C Blue #2, FD&C Red #40, iron oxide black, propylene glycol, and shellac.
The invention relates to a space mutation excellent microbial strain, in particular to a screening preparation method and an application of a space mutation high-efficiency enterococcus faecalis. The enterococcus faecalis is the most common in the enterococcus and is a representative type. The enterococcus faecalis lives in the human intestinal tract and is not harmful to the human body but is beneficial to the human body. However, the enterococcus faecalis causes serious infection sometimes and has resistance to the antibiotics. The common enterococcus faecalis is selected to perform the space treatment. The space mutation high-efficiency enterococcus faecalis is screened and bred finely by the space mutation and is taken as a producing strain. The bacteriuml strain with great vitality, high growth rate, high ferment unit, short ferment cycle, high content of ferment product and strong production adaptability is taken as the producing strain; the ferment fluid is purified finely through the primary ferment and the secondary ferment and has the function of adjusting immunizing power and the anti-tumor function, etc.
Patients undergo genetic testing on previously-collected tissue. Patients receive one of the following treatment regimens per treating physician: 1)Cabazitaxel IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. 2)Abiraterone acetate PO QD on days 1-28 of each cycle and prednisone PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. 3) Enzalutamide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. 4) Lutetium Lu 177 vipivotide tetraxetan IV on day 1 of each cycle. Treatment repeats every 42 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT and bone scan throughout the trial. Patients may also undergo optional FDG or PSMA PET, as well as optional blood collection throughout the trial.
BACKGROUND/AIMS: This study examined the effects of a specially designed energy-restricted diet with alternate carbohydrate intake on body composition and cardiometabolic risk factors in overweight and obese adults. The aim was to assess whether the intervention could lead to significant weight loss, improve body composition, and reduce cardiometabolic risks.
METHODS: Sixty-five participants (34 women, 31 men) with an average BMI of 31.8 ± 9.1 kg/m2 (women) and 34.1 ± 6.4 kg/m2 (men) participated in a 14-week intervention. The diet included different days of carbohydrate intake and a 20% reduction in total daily energy consumption. Anthropometric measurements and biochemical parameters, including predictive indices of cardiometabolic risk, were determined at baseline and after the intervention.
RESULTS: The intervention resulted in a significant reduction in body weight (mean weight loss of 17%, p < 0.001), with 64.6% of participants achieving a weight loss of at least 10%. Muscle mass as a percentage of total body weight increased. Cardiometabolic improvements were observed in fasting blood glucose (from 5.4 to 4.9 mmol/L, p < 0.001) and LDL cholesterol (from 3.38 to 2.81 mmol/L, p < 0.001). Gender-specific differences were found, particularly in HDL-C, which decreased significantly in women (p = 0.013), while there was a non-significant increase in men. Cardiometabolic indices, including the Visceral Adiposity Index (VAI) and the Cardiometabolic Index (CMI), also improved significantly.
CONCLUSIONS: The alternate carbohydrate diet improved body composition, cardiometabolic health, and treatment adherence through metabolic flexibility. However, the short duration of this study and the lack of a control group suggest that further research is needed to assess long-term sustainability.
Infants born at 37 weeks gestational age or greater born to mothers of any age with uncomplicated pregnancies. Following delivery, cord blood obtained from the placental portion of the umbilical cord will be used for analysis. To assure appropriate dilution, a hematocrit will be measured at the time of blood collection using a blood gas machine for prompt results. Sample blood will immediately be taken by the investigators from the delivery hospital to the children's hospital where the following clotting studies will be performed: PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s. Specimens will be transported utilizing Specimen Transport Guidelines.
Patients with disease progression during or after prior anti-PD-1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment receive durvalumab (IV over 60 minutes) and tremelimumab (IV over 60 minutes) on day 1 for courses 1-4 and durvalumab IV alone on day 1 of course 5 and subsequent courses until disease progression or unacceptable toxicity. Courses repeat every 28 days.
The issue of emergency care for traumatic bleeding is of particular relevance in modern medicine due to widespread military conflicts. This characterizes the need to summarize available data on hemostatic agents in combat conditions. This review of available literature is devoted to systemic and local hemostatic agents, as well as devices for temporary bleeding arrest. The most promising local hemostatic agents are chitosan-based products. Systemic hemostatic agents are represented by various forms and require further clinical trials. Modern tourniquets significantly reduce the mortality rate in extreme conditions and significantly exceed their historical counterparts in convenience and efficiency.
The invention provides a cancer pain plaster composed of nux vomica, Hindu datura flower, pendulous monkshood root, dried Chinese toad skin, paniculate swallowwort root or herb, yanhusuo tuber, panax notoginseng, and an auxiliary material of borneol. One plaster comprises, preferably, 1.0g of nux vomica, 1.0g of Hindu datura flower, 1.0g of pendulous monkshood root, 1.0g of dried Chinese toad skin, 1.0g of paniculate swallowwort root or herb, 2.0g of yanhusuo tuber, 1.0g of panax notoginseng, and the auxiliary material of borneol. According to the technology, authentic pure traditional Chinese medicines are selected, and scientific formulation and rigorous production process are adopted. The materials are refined, and effect is concentrated. An effect can be provided after 20min of application, and a pain-relieving effect can last for 24h. Therefore, a substantial pain-relieving effect can be provided for continuous cancer pain. Especially, the plaster has relieving and stopping effects against long-term severe pains. When the plaster is repeatedly applied, no toxic or side effect is provided, and addiction is prevented. The plaster causes no irritation or allergy to skins, and is suitable to be used against various pains caused by various cancer primary tumors and metastases. With the plaster, patient pain can be relieved, symptoms can be relieved, and substantial pain relieving effects and concentrated pain relieving functions such as blood circulation activating, stasis removing, collateral dredging, qi regulating, and stagnation eliminating are provided.
The topical therapy for androgenetic alopecia is still not enough to improve cosmetically. Thereforem we try to find new effective and safe topical therapy for this disease. Roxithromycin has not only antibacterial action but also immunomodulatory and anti-inflamatory potency. For example, roxitromycin inhibits T cell responces to mitogens and production of cytokines, IL-2 and IL-5. We firstly found that roxitromycin increased human and murine hair elongation in vitro to inhibit apoptosis of hair bulb. Then, we wish to apply roxithromycin on the therapy for androgenetic alopecia.
The oxycodone in Oxycodone Hydrochloride and Acetaminophen Tablets may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control during Oxycodone Hydrochloride and Acetaminophen Tablets therapy.

###  Withdrawal 

Avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including Oxycodone Hydrochloride and Acetaminophen Tablets. In these patients, mixed agonist/antagonist and partial analgesics may reduce the analgesic effect and/or precipitate withdrawal symptoms. 

When discontinuing Oxycodone Hydrochloride and Acetaminophen Tablets, gradually taper the dosage [see DOSAGE AND ADMINISTRATION]. Do not abruptly discontinue Oxycodone Hydrochloride and Acetaminophen Tablets [see DRUG ABUSE AND DEPENDENCE].
Epilepsy, a condition characterized by spontaneous recurrent epileptic seizures, is among the most prevalent neurological disorders. This disorder is estimated to affect approximately 70 million people worldwide. Although antiseizure medications are considered the first-line treatments for epilepsy, most of the available antiepileptic drugs are not effective in nearly one-third of patients. This calls for the development of more effective drugs. Evidence from animal models and epilepsy patients suggests that strategies that interfere with the P2X7 receptor by binding to adenosine triphosphate (ATP) are potential treatments for this patient population. This review describes the role of the P2X7 receptor signaling pathways in epileptogenesis. We highlight the genes, purinergic signaling, Pannexin1, glutamatergic signaling, adenosine kinase, calcium signaling, and inflammatory response factors involved in the process, and conclude with a synopsis of these key connections. By unraveling the intricate interplay between P2X7 receptors and epileptogenesis, this review provides ideas for designing potent clinical therapies that will revolutionize both prevention and treatment for epileptic patients.
The application provides a medical system electronic body temperature measuring system and method based on a wireless ad hoc network technology. The medical wireless electronic thermometer comprises a medical wireless electronic thermometer, a relay node, a root node gateway, a router, a server and management software. The wireless electronic thermometer and the server use a wireless ad hoc network technology to transmit temperature data. The wireless electronic thermometer comprises a digital temperature sensor, an MCU and a wireless transmission module, local display and real-time wireless transmission of data are realized, and the wireless electronic thermometer is in a dormant state at idle time so as to reduce power consumption. The relay node is composed of a wireless transmission module and transmits the data of the wireless electronic thermometer to a server of the monitoring center. The application relates to a wireless electronic body temperature measuring system and method based on the Internet of things technology, which can realize automatic measurement, real-time reporting and intelligent processing of the body temperature of a patient, reduce the workload of medical personnel, grasp the body temperature data of the patient in time, perform intelligent analysis and comparison on the data and provide scientific basis for treatment.
The dual microbial preparation contains the microscopic oomycete Pythium oligandrum and components of a physiological microbiome. The microscopic oomycete Pythium oligandrum and the physiological microbiome component are present in the dual preparation in a form which facilitates their germination, subsequent propagation and colonization of the target tissues. The microscopic oomycete Pythium oligandrum is incorporated in a quantity of 103 to 107 CFU (colony forming units), with 104 to 105 CFU per one cycle of application preferably. The physiological microbiome component contains 5x 106 to 5x1010 CFU, with 5x107 to 5x109 per one cycle of application preferably. The fermented substrate found in the Pythium oligandrum oomycete is the source of nutrients for both microbial components. The dual microbial preparation also contains at least one auxiliary substance from a group including a desiccant, components of a buffer system, an anti-caking substance and an agent for the creation of a physiological osmotic environment. The physiological microbiome component is a component of the human microbiome, one of the microbes of the green complex, such as the Capnocytophaga sputigena bacterium, or one of the components of the healthy skin microbiome, such as the Staphyloccocus epidermidis bacterium, or one of the components of the healthy vaginal microbiome, such as the peroxide producing Lactobacillus crispatus. Either the microscopic oomycete Pythium oligandrum or the physiological microbiome component is present in the dual microbial preparation in the form of inactivated cells, cell extracts or isolated cell fractionation. The microbial activator for the Pythium oligandrum oomycete is a yeast autolysate in a quantity of 0.1 % to 10 % weight of the total quantity of dual microbial preparation. The auxiliary substances are regulated in a way which allows for application in the form of an ointment, cream, oil or suppository or in the form of a liquid aqueous preparation.